Clinical trials: Basal Cell Cancer
Sporadic Superficial and Nodular Skin Basal Cell Carcinomas
To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)
This was a double-blinded, randomized, vehicle-controlled study in sporadic superficial BCC (sBCC) and nodular BCC (nBCC) patients which consisted of a 21-day screening period, a treatment period of 6 weeks (topical 0.75% LDE225…
- Trial name
- NCT01033019
- Testing
- LDE225 0.75%, Vehicle
- Where
- 4 sites in Australia, Austria
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Basal Cell Carcinoma, Gorlin Syndrome
Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
This was a phase II, double-blind, randomized, proof-of-concept, dose-ranging trial evaluating the efficacy, safety and pharmacokinetics of oral LDE225 in treatment of adult patients with NBCCS.
- Conditions
- Basal Cell Carcinoma, Gorlin Syndrome, Nevoid Basal Cell Carcinoma Syndrome
- Trial name
- NCT01350115
- Testing
- LDE225
- Where
- 6 sites in Austria, Belgium and 2 more
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Basal Cell Carcinoma
A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
This is an open-label, non-comparative, multicenter, expanded access study of Vismodegib (GDC-0449) in patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC (mBCC) who are otherwise without satisfactory…
- Trial name
- NCT01160250
- Testing
- vismodegib (GDC-0449)
- Where
- 11 sites in United States
- Sponsor
- Genentech, Inc.
Skin Neoplasms
Safety Study of a Fluorescent Marker to Visualize Cancer Cells
Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed.
- Trial name
- NCT02097875
- Testing
- BLZ-100
- Where
- Australia
- Volunteers
- 21 people
- Sponsor
- Blaze Bioscience Australia Pty Ltd
Basal Cell Carcinoma
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma
The purpose of this study is to determine whether topical application of PEP005 is safe for the treatment of nodular basal cell carcinoma.
- Trial name
- NCT00108121
- Testing
- PEP005
- Where
- 10 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Peplin
Hedgehog Pathway, Smoothened
A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer
The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule
- Conditions
- Hedgehog Pathway, Smoothened, Basal Cell Carcinoma (BCC), Basal Cell Nevoid Syndrome (BCNS)
- Trial name
- NCT00670189
- Testing
- BMS-833923 (XL139)
- Where
- 3 sites in United States, Canada
- Volunteers
- 53 people
- Sponsor
- Bristol-Myers Squibb
Basal Cell Carcinoma
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
This was a 3-cohort, open-label study of vismodegib (GDC-0449) in new (non-recurrent) operable basal cell carcinoma of the nodular subtype.
- Trial name
- NCT01201915
- Testing
- Vismodegib
- Where
- 12 sites in United States
- Volunteers
- 74 people
- Sponsor
- Genentech, Inc.
Advanced Nonhematologic Malignancies, Carcinoma, Basal Cell
A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies
This is the first study in which TAK-441 is administered to humans. The patient population will consist of adults aged 18 or older who have advanced nonhematologic malignancies and for whom standard treatment is no longer…
- Trial name
- NCT01204073
- Testing
- TAK-441
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Basal Cell Carcinoma, Chondrosarcoma
IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
A treatment protocol that enables patients to have continued access to IPI-926.
- Trial name
- NCT01609179
- Testing
- IPI-926
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Basal Cell Carcinoma, Nevoid Basal Cell Carcinoma Syndrome
Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.
The purpose of the two studies is to determine whether an experimental therapy using a photoactive drug, verteporfin, in combination with direct light exposure of basal cell carcinoma of the skin can safely eliminate these skin…
- Conditions
- Basal Cell Carcinoma, Nevoid Basal Cell Carcinoma Syndrome, Gorlin Syndrome
- Trial name
- NCT00049959
- Testing
- verteporfin PDT
- Sponsor
- QLT Inc.
Superficial Basal Cell Carcinoma
Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream
An open-label study to evaluate the safety and the ability of Imiquimod 5% cream, applied topically, to clear superficial basal cell carcinoma and to keep it clear for 5 years of follow-up.
- Trial name
- NCT00189306
- Testing
- Imiquimod 5% cream
- Where
- 18 sites in Australia, New Zealand
- Volunteers
- 169 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Basal Cell Carcinoma
A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence
The primary objective of this study is to assess whether basal cell carcinoma (BCC) lesions surgically treated with curettage, followed by imiquimod 5% cream as postsurgical adjuvant therapy, will have an improved cure rate over…
- Trial name
- NCT00129519
- Testing
- Imiquimod 5% cream
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Basal Cell Carcinoma
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma
The purpose of this study is to determine whether topical application of PEP005 is safe for the treatment of superficial basal cell carcinoma.
- Trial name
- NCT00108134
- Testing
- PEP005
- Where
- 9 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Peplin